Clarity Pharmaceuticals Overview
- Year Founded
-
2010
- Status
-
Public
- Employees
-
23
- Stock Symbol
-
CU6
- Share Price
-
$1.40
- (As of Thursday Closing)
Clarity Pharmaceuticals General Information
Description
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation products that improve treatment outcomes for people with cancer. Its products use the perfect pairing of copper isotopes, copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy, which deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers. Its core clinical-stage programs, SAR-bisPSMA, SARTATE and SAR-Bombesin, each contain a different targeting agent that binds to specific receptors that are present on different cancer cells. It operates as one segment Development of Radiopharmaceuticals in Australia and the United States.
Contact Information
Website
www.claritypharmaceuticals.comCorporate Office
- 4 Cornwallis Street, National Innovation Centre
- Suite 212a
- Eveleigh, New South Wales 2015
- Australia
Corporate Office
- 4 Cornwallis Street, National Innovation Centre
- Suite 212a
- Eveleigh, New South Wales 2015
- Australia
Clarity Pharmaceuticals Timeline
Clarity Pharmaceuticals Stock Performance
As of 12-Nov-2026, Clarity Pharmaceuticals’s stock price is $1.40. Its current market cap is $523M with 373M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.40 | $1.15 | $0.93 - $3.01 | $523M | 373M | 2.57M |
Clarity Pharmaceuticals Financials Summary
As of 30-Sep-2026, Clarity Pharmaceuticals has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | 422,956 | 393,582 | 452,325 | 1,098,057 |
| EBITDA | (77,229) | (44,293) | (29,259) | |
| Net Income | (72,649) | (41,600) | (27,737) | |
| Total Assets | 136,994 | 66,084 | 103,354 | |
| Total Debt | 0 | 0 | 0 |
Clarity Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Clarity Pharmaceuticals Comparisons
Industry
Financing
Details
Clarity Pharmaceuticals Competitors (7)
One of Clarity Pharmaceuticals’s 7 competitors is Navidea Biopharmaceuticals, a Corporate Backed or Acquired company based in Columbus, OH.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Navidea Biopharmaceuticals | Corporate Backed or Acquired | Columbus, OH | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Pyxis Oncology | Formerly VC-backed | Boston, MA | ||||
| Linnaeus Therapeutics | Venture Capital-Backed | Haddonfield, NJ | ||||
| Bolt Biotherapeutics | Formerly VC-backed | Redwood City, CA |
Clarity Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Clarity Pharmaceuticals Patents
Clarity Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025905152-A0 | Cancer targeting compounds and methods for their production | Pending | 29-Oct-2025 | ||
| AU-2025901348-A0 | Formulations of radiopharmaceuticals complexed with copper | Pending | 17-Apr-2025 | ||
| WO-2026218065-A1 | Formulations of radiopharmaceuticals complexed with copper | Pending | 17-Apr-2025 | ||
| AU-2025900189-A0 | Combination cancer therapy | Inactive | 24-Jan-2025 | ||
| WO-2026156406-A1 | Combination cancer therapy | Pending | 24-Jan-2025 | A61K51/04 |
Clarity Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Clarity Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Clarity Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Clarity Pharmaceuticals FAQs
-
When was Clarity Pharmaceuticals founded?
Clarity Pharmaceuticals was founded in 2010.
-
Where is Clarity Pharmaceuticals headquartered?
Clarity Pharmaceuticals is headquartered in Eveleigh, Australia.
-
What is the size of Clarity Pharmaceuticals?
Clarity Pharmaceuticals has 23 total employees.
-
What industry is Clarity Pharmaceuticals in?
Clarity Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Clarity Pharmaceuticals a private or public company?
Clarity Pharmaceuticals is a Public company.
-
What is Clarity Pharmaceuticals’s stock symbol?
The ticker symbol for Clarity Pharmaceuticals is CU6.
-
What is the current stock price of Clarity Pharmaceuticals?
As of 12-Nov-2026 the stock price of Clarity Pharmaceuticals is $1.40.
-
What is the current market cap of Clarity Pharmaceuticals?
The current market capitalization of Clarity Pharmaceuticals is $523M.
-
Who are Clarity Pharmaceuticals’s competitors?
Navidea Biopharmaceuticals, Immunocore Holdings, Pyxis Oncology, Linnaeus Therapeutics, and Bolt Biotherapeutics are some of the 7 competitors of Clarity Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
